The treatment landscape of Ph+ ALL has been reshaped over the past two decades with the introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs), resulting in dramatic improvements in long-term survival [1,2]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.